MENU
AYTU
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

AYTU stock forecast, quote, news & analysis

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products... Show more

AYTU
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for AYTU with price predictions
Sep 23, 2026

AYTU in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 09, 2026

AYTU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 42 of 52 cases where AYTU's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AYTU's RSI Indicator exited the oversold zone, 31 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on AYTU as a result. In 68 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for AYTU just turned positive on September 22, 2026. Looking at past instances where AYTU's MACD turned positive, the stock continued to rise in 39 of 52 cases over the following month. The odds of a continued upward trend are 75%.

AYTU moved above its 50-day moving average on September 22, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +7.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where AYTU advanced for three days, in 165 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for AYTU crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AYTU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for AYTU entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.679) is normal, around the industry mean (43.851). P/E Ratio (0.005) is within average values for comparable stocks, (141.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.193). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.320) is also within normal values, averaging (178.797).

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. AYTU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AYTU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.15B. The market cap for tickers in the group ranges from 2.12K to 66.17B. MKGAF holds the highest valuation in this group at 66.17B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 4%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 43%. IMCC experienced the highest price growth at 79%, while SBFM experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 6%. For the same stocks of the Industry, the average monthly volume growth was 12% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 63
Price Growth Rating: 55
SMR Rating: 87
Profit Risk Rating: 82
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
AYTU
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals

Industry PharmaceuticalsGeneric

Industry
Other Consumer Services
Address
7900 East Union Avenue
Phone
+1 720 437-6580
Employees
83
Web
https://www.aytubio.com
AYTU in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 09, 2026